Mittwoch, 24. Mai 2017


  • Pressemitteilung BoxID 544940

Ypsomed doubles dividends to shareholders

(lifePR) (Burgdorf, ) The shareholders of Ypsomed Holding AG approved all proposals by the board of directors by a large majority at the regular general meeting held on 1st July 2015. For the 2014/15 fiscal year, a dividend of CHF 0.60 per share, exempt from withholding tax, will be paid to shareholders from capital reserves.

The shareholders approved all amendments to the statutes that were mainly required by the Ordinance Against Excessive Compensation in Swiss Listed Companies. The directors, Dr. h.c. Willy Michel, Anton Kräuliger, Prof. em. Norbert Thom and Gerhart Isler, have been reelected to their offices for one year until the next regular annual general meeting. Dr. h.c. Willy Michel was approved as president of the board of directors for the same period. For the first time, the shareholders also decided on the remuneration for the board of directors and management. They approved the respective proposals of the board of directors.

Ypsomed AG

The Ypsomed Group is the leading developer and manufacturer of injection systems for self-medication and a renowned diabetes specialist with 30 years of experience. Founded in 2003 from the well-known company Disetronic Medical Systems, today it offers insulin pumps and injection systems as well as pen needles for the treatment of diabetes, growth disorders, infertility, autoimmune diseases, oncology and other therapeutic areas. Ypsomed is regarded as a leader in innovation and technology and is the preferred partner of pharmaceutical and biotech companies in the self-medication field. Ypsomed has established itself with the umbrella brands mylife™ Diabetescare and YDS™ Ypsomed Delivery Systems in retailing and in business-to-business trading respectively. Under the brand name mylife™ Diabetescare, Ypsomed offers patients an extensive range of self-manufactured products or commercial products for the treatment of diabetes. The range from YDS™ reflects the many years of experience and competence in the field of injection systems. With an innovative and patent-protected product portfolio of pen systems and autoinjectors, which can be adapted to customer requirements, and contract development and manufacturing, Ypsomed provides customer orientated product and service solutions to pharmaceutical and biotech companies worldwide.

Ypsomed has its headquarters in Burgdorf in Switzerland and owns several manufacturing sites in Switzerland and in the Czech Republic. Ypsomed has its own subsidiaries throughout Europe and works with leading, independent marketing partners worldwide. The Ypsomed Group has around 1,100 employees.

Diese Pressemitteilungen könnten Sie auch interessieren

TÜV SÜD gibt Sicherheitstipps für das Online-Banking

, Finanzen & Versicherungen, TÜV SÜD AG

Mit mobilen Geräten wie Smartphones oder Tablets lassen sich immer mehr Alltagssituationen vereinfachen. Auch das Erledigen der eigenen Bankgeschäfte...

Dussmann Group komplettiert den Vorstand und legt auch 2016 wieder zu

, Finanzen & Versicherungen, Dussmann Stiftung & Co. KGaA

Drei neue Vorstandsmitglieder werden im August 2017 den Vorstand komplettieren: Dr. oec. Wolfgang Häfele, Dieter A. Royal und Wolf-Dieter Adlhoch Gesamtumsatz...

Doch die meisten GKV-Versicherten gehen weiter leer aus

, Finanzen & Versicherungen, uniVersa Versicherungen

Seit Mitte April zahlen Krankenkassen wieder leichter Zuschüsse bei Erwachsenen für Brillen. Möglich macht dies das Gesetz zur Stärkung der Heil-...

Disclaimer